Latest News

This technology-driven insurer, focused on residential markets, reported significant insider selling in its latest SEC filing.

Ford took a $19.5 billion noncash charge just months ago and has turned that into a big triumph with its new venture.

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions. Speaking at a Jefferies fireside c

The space sector is lifting off as SpaceX approaches its IPO.

Alphabet is signaling continues investments in AI.

Sales are booming as consumers flock to places that offer value.

Nvidia continues to deliver excellent financial performance, while the stock price increases only modestly.

Some investors fear that Broadcom stock has peaked. That could be a costly mistake.

Rubrik soared last month, but not entirely on its own merits. Here's the real story behind the surge.

S&P Dow Jones is considering altering its index admission policy to fast-track their entries.

Modern businesses operate in an environment where sales cycles are faster, customer expectations are higher, and competition is more intense than ever befo

Joby Aviation is becoming a leader in the eVTOL industry.

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference. Erik, Akebia’s chief financial offic

Canadian companies building AI infrastructure are powering the nation’s digital future. Here’s why Hydro One, Emera, and Brookfield Infrastructure matter.

Calvin Klein and Tommy Hilfiger have seen better days.

The stock merely surrendered gains accumulated over the past week.

It's testing a new, blockchain-based method of settling transactions.

This regional lender with a commercial focus reported a notable insider sale amid a year of double-digit stock gains.

The AI build-out continues to pick up steam.

Focused on automotive semiconductors and smart vehicle tech, this company reported a notable insider sale amid strong recent stock gains.

As a specialty insurer in credit protection, this firm reported significant insider selling amid a year of share price decline.

Looking past the hype reveals some big risks that potential SpaceX investors should consider.

The One Big Beautiful Bill Act (OBBBA) revolutionized payroll forever. It was signed into law on July 4, 2025 and provided a federal income tax exemption o

Join us as we dissect Merck's stock potential and the challenges it faces with the impending patent cliff of Keytruda. Can this pharmaceutical giant maintain its edge in the market?